Home
About
Overview
Sharing Data
ORCID
Help
History (24)
Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy.
Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study.
Radiomic prediction of mutation status based on MR imaging of lung cancer brain metastases.
Pathologic Considerations and Standardization in Mesothelioma Clinical Trials.
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping.
See All 24 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping.
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping. Cancer Treat Rev. 2020 Jul; 87:102022.
View in:
PubMed
subject areas
Animals
Carcinoma, Non-Small-Cell Lung
Exons
Humans
Lung Neoplasms
Protein Kinase Inhibitors
Proto-Oncogene Proteins c-met
Randomized Controlled Trials as Topic
Xenograft Model Antitumor Assays
authors with profiles
Ravi Salgia